In 2004, Dr Prow earned his Ph.D. from the University of Texas in the field of Nanomedicine. He then completed his T32 funded post-doc at the Wilmer Eye Institute at The Johns Hopkins Hospital and was faculty there until he relocated to the University of Queensland in Brisbane, Australia in 2007. In 2011 Dr Prow became the Deputy Director of the Dermatology Research Centre. In 2015, Dr Prow was promoted to Associate Professor within the University of Queensland's School of Medicine. He leads a NHMRC and ARC funded team that focuses on drug delivery, diagnostics and imaging in the context of dermatology.
Drug delivery (NHMRC funded): Topical treatment is an attractive management approach for treating skin lesions. Unfortunately, many potentially therapeutic drugs have poor skin penetration profiles. We have developed and patented a novel platform for field- or lesion-directed drug delivery, Foroderm™. This technology is based on high-aspect ratio microparticles that were engineered to only penetrate the stratum corneum and viable epidermis.
Diagnostics (ARC funded): Minimally invasive microneedle-based biopsies could hold the key for molecular detection of skin cancer. We have developed a stacked 3D microneedle device for instantaneously capturing small pieces of skin from suspicious lesions.
Imaging and image analysis (CCQ funded): Skin cancer diagnosis is moving toward more accurate, non-invasive approaches with in vivo imaging techniques at the forefront (e.g. reflectance confocal microscopy, multiphoton tomography and optical coherence tomography). We have begun developing automated RCM analysis approaches that enable objective photoageing analysis to objectively quantify solar damage. This effort has also lead to our development of novel approaches for identifying signs of precancerous lesions in clinical photographs.